Toboroz
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
NCT07361510· 3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
Phase 2 Study of AHB-137 in HBeAg Negative Chronic Hepatitis B (CHB) Participants in Asia Pacific Region
NCT07370207· 2. fázis· AusperBio Therapeutics Inc.· Forrás
Toboroz
Hybrid Stroke Rehab With Mirror Priming
NCT07324278· I-Shou University· Forrás
Toboroz
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
NCT07100080· 2/3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06793215· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
NCT07165028· 3. fázis· Eli Lilly and Company· Forrás
Toboroz
Nightly Wearable Monitoring During Home-Based Submental Electrical Stimulation for Obstructive Sleep Apnea
NCT07921329· E-DA Hospital· Forrás
Toboroz
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
NCT06935370· 3. fázis· Boehringer Ingelheim· Forrás
Toboroz
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
NCT06890598· 3. fázis· Eli Lilly and Company· Forrás
Toboroz
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819878· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
NCT06632444· 3. fázis· Boehringer Ingelheim· Forrás
Fut, nem toboroz
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
NCT06531824· 3. fázis· Boehringer Ingelheim· Forrás
Fut, nem toboroz
Clinical Performance Evaluation of RDX-Aneurysm for Detecting Intracranial Aneurysms on TOF-MRA
NCT07655635· Taipei Medical University Shuang Ho Hospital· Forrás
Toboroz
Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729)
NCT06277037· Arbutus Biopharma Corporation· Forrás
Toboroz
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
NCT06424288· 3. fázis· Boehringer Ingelheim· Forrás
Meghívásos bevonás
ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study
NCT06194799· 3. fázis· ACADIA Pharmaceuticals Inc.· Forrás
Fut, nem toboroz
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
NCT06012435· 3. fázis· Seagen, a wholly owned subsidiary of Pfizer· Forrás
Fut, nem toboroz
MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
NCT06132256· 2. fázis· Syndax Pharmaceuticals· Forrás
Toboroz
ACP-204 in Adults With Alzheimer's Disease Psychosis
NCT06159673· 2/3. fázis· ACADIA Pharmaceuticals Inc.· Forrás
Fut, nem toboroz
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
NCT05757869· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
The Prevalence, Risk Factors and Optimal Biopsy Protocol of BE
NCT05818072· E-DA Hospital· Forrás
Fut, nem toboroz
Finite Versus Continuous Nucleos(t)Ide Analogues for Chronic Hepatitis B
NCT05793268· E-DA Hospital· Forrás
Toboroz
Taiwan Real-world LDCT Screening Behavior and Outcome Research for High Risk Subjects Based on Health Promotion Administration
NCT05557487· Gee-Chen Chang· Forrás
Toboroz
Formatting the Risk Prediction Models for Never-Smoking Lung Cancer
NCT05572944· Chung Shan Medical University· Forrás
Fut, nem toboroz
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
NCT05502237· 3. fázis· Gilead Sciences· Forrás
Fut, nem toboroz
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
NCT05462717· 1. fázis· Revolution Medicines, Inc.· Forrás
Meghívásos bevonás
Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
NCT04905693· 3. fázis· United Therapeutics· Forrás
Fut, nem toboroz
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
NCT05338970· 3. fázis· Daiichi Sankyo· Forrás
Fut, nem toboroz
Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)
NCT05186974· 2. fázis· Gilead Sciences· Forrás
Fut, nem toboroz
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
NCT05215340· 3. fázis· Daiichi Sankyo· Forrás
Fut, nem toboroz
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
NCT05091567· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
NCT04680052· 3. fázis· Incyte Corporation· Forrás
Fut, nem toboroz
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
NCT04619004· 2. fázis· Daiichi Sankyo· Forrás
Fut, nem toboroz
Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)
NCT04656652· 3. fázis· Daiichi Sankyo· Forrás
Fut, nem toboroz
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT04487080· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
Chronic Hepatitis b Patients Switch to tAf After Discontinuation of Nucleoside Analogue
NCT04496882· 4. fázis· National Taiwan University Hospital· Forrás
Fut, nem toboroz
Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance
NCT04285086· 3. fázis· PharmaEssentia· Forrás
Fut, nem toboroz
A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
NCT04194944· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
Statin for Preventing Hepatocellular Carcinoma Recurrence After Curative Treatment
NCT03024684· 4. fázis· Chiayi Christian Hospital· Forrás
Fut, nem toboroz
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)
NCT02411448· 3. fázis· Eli Lilly and Company· Forrás